Jpmorgan Chase & CO Xoma Corp Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Xoma Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12,089 shares of XOMA stock, worth $284,333. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,089

Previous 3,567 238.91%

Holding current value

$284,333

Previous $94,000 237.23%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$25.11 - $33.88 $213,987 - $288,725	8,522 Added 238.91%	12,089 $317,000
Q2 2024 Aug 12, 2024	BUY	$22.31 - $26.7 $7,451 - $8,917	334 Added 10.33%	3,567 $84,000
Q1 2024 Dec 26, 2024	SELL	$19.1 - $26.32 $6,379 - $8,790	-334 Reduced 9.36%	3,233 $77,000
Q1 2024 May 10, 2024	SELL	$19.1 - $26.32 $33,596 - $46,296	-1,759 Reduced 35.24%	3,233 $77,000
Q4 2023 Dec 26, 2024	BUY	$13.82 - $19.13 $19,693 - $27,260	1,425 Added 39.95%	4,992 $92,000
Q4 2023 Feb 12, 2024	SELL	$13.82 - $19.13 $1,851 - $2,563	-134 Reduced 2.61%	4,992 $92,000
Q3 2023 Nov 14, 2023	SELL	$14.02 - $17.71 $15,253 - $19,268	-1,088 Reduced 17.51%	5,126 $72,000
Q2 2023 Aug 11, 2023	BUY	$17.0 - $21.58 $99,059 - $125,746	5,827 Added 1505.68%	6,214 $117,000
Q1 2023 May 11, 2023	BUY	$18.01 - $23.12 $6,861 - $8,808	381 Added 6350.0%	387 $8,000
Q2 2022 Aug 11, 2022	SELL	$17.05 - $28.22 $48,166 - $79,721	-2,825 Reduced 99.79%	6 $0
Q1 2022 May 11, 2022	SELL	$19.62 - $29.61 $4,120 - $6,218	-210 Reduced 6.91%	2,831 $79,000
Q4 2021 Feb 10, 2022	SELL	$20.04 - $27.57 $8,016 - $11,028	-400 Reduced 11.62%	3,041 $63,000
Q3 2021 Nov 12, 2021	BUY	$23.51 - $34.79 $80,897 - $119,712	3,441 New	3,441 $85,000

Others Institutions Holding XOMA

# of Institutions

Shares Held

6.63M

Call Options Held

1.2K

Put Options Held

2.2K

View Full List

About XOMA Corp

Ticker XOMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,450,800
Market Cap $269M
Description
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolog...

More about XOMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Xoma Corp Transaction History